ReviewVascular health and risk management2011
Benefits of once-daily therapies in the treatment of hypertension.
Review in Vascular health and risk management, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 55 citations in OpenAlex.
- Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- The effect of evening vs. morning medication on morning blood pressure surge.Scientific reports · 2026Article
- An assessment of treatment compliance using the Morisky scale-8 tool in adult hypertensive patients of Eastern India.Journal of family medicine and primary care · 2024Article
- Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit.Advances in therapy · 2023Review
- Suboptimal control status of young hypertensive population.Clinical hypertension · 2023Review
- Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022Article
- Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient.Therapeutic advances in chronic disease · 2022Review
- US trends in premature heart disease mortality over the past 50 years: Where do we go from here?Trends in cardiovascular medicine · 2020Review
- Once versus twice daily antihypertensive medications for the control of nocturnal blood pressure: a comparative study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2020Article
- Coordination of cardiac rhythmic output and circadian metabolic regulation in the heart.Cellular and molecular life sciences : CMLS · 2018Review
- Beating against the clock.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Article
- Chronotherapy improves blood pressure control and reduces vascular risk in CKD.Nature reviews. Nephrology · 2013Review
- Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?Vascular health and risk management · 2013Review
- Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study.Vascular health and risk management · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with hypertension, 24-hour blood pressure control is the major therapeutic goal. The number of daily doses is one characteristic of an antihypertensive agent that may affect the adequacy of 24-hour control. One measure of therapeutic coverage is the 24-hour trough-to-peak ratio, which determines the suitability of an agent for once-daily administration. The closer an agent is to a 100% trough-to-peak ratio, the more uniform the 24-hour coverage and therefore blood pressure control. High trough-to-peak ratio, long-acting antihypertensive medications lower blood pressure more gradually, which reduces the likelihood of adverse events attributable to abrupt drug action that occurs with shorter-acting agents. In hypertension, the natural diurnal variation of blood pressure may be altered, including elevated nighttime pressures. An optimal once-daily hypertension therapy would not only lower blood pressure but also normalize any blunted circadian variations in blood pressure. The benefits of once-daily agents with sustained therapeutic coverage may also be explained, in part, by increased patient adherence to simpler regimens as well as lower loss of blood pressure control during virtually inevitable intermittent noncompliance. Studies have demonstrated that once-daily antihypertensive agents have the highest adherence compared with twice-daily or multiple daily doses, including greater adherence to the prescribed timing of doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.